Neurocrine Biosciences | Bénéfice Avant Impôts



Pre Tax Profit Changement Date
AbbVie USD 4.81B 1.54B 2024-12
Acadia Pharmaceuticals USD 27.78M 133.31M 2025-03
Agios Pharmaceuticals USD -89289000 16.11M 2025-03
ALKERMES USD 443.75M 333.52M 2024-12
Alnylam Pharmaceuticals USD -41596000 152.36M 2025-03
Amgen USD 3.38B 111M 2024-12
Biogen USD 572.2M 118.5M 2024-12
BioMarin Pharmaceutical USD 169.64M 35.2M 2024-12
Cytokinetics USD -161376000 11.36M 2025-03
Dynavax Technologies USD -97875000 105.5M 2025-03
Exelixis USD 205.69M 20.92M 2025-03
Gilead Sciences USD 2.96B 112M 2024-12
Halozyme Therapeutics USD 557.13M 359.8M 2024-12
Incyte USD 234.19M 172.64M 2025-03
Ionis Pharmaceuticals USD -147000000 40M 2025-03
Neurocrine Biosciences USD 162.6M 27.7M 2024-12
Pfizer USD 4.44B 2.36B 2024-12
Prothena USD -59501000 335K 2024-12
Regeneron Pharmaceuticals USD 905M 53.1M 2025-03
Repligen USD 7.94M 46.55M 2025-03
Sarepta Therapeutics USD -383518000 555.26M 2025-03
Teva Pharmaceutical Industries USD 294M 605M 2025-03
Ultragenyx Pharmaceutical USD -133404000 191K 2024-12
Vertex Pharmaceuticals USD 1.32B 109.7M 2024-12



Neurocrine Biosciences Bénéfice Avant Impôts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.